source
- Revolution Medicines' daraxonrasib nearly doubles survival in pancreatic cancer trialData presented at the American Society of Clinical Oncology meeting showed that Revolution Medicines' experimental drug daraxonrasib significantly extended survival for patients with metastatic pan…
- Ivonescimab cuts death risk by 34% in Chinese trial for squamous NSCLCData presented at the American Society of Clinical Oncology showed that ivonescimab, a bispecific antibody combining two established cancer drugs, lowered the risk of death by 34% compared with sta…